Rise in broadly cross-reactive adaptive immunity against human β-coronaviruses in MERS-recovered patients during the COVID-19 pandemic
To develop a universal coronavirus (CoV) vaccine, long-term immunity against multiple CoVs, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, Middle East respiratory syndrome (MERS)-CoV, and future CoV strains, is crucial. Following the 2015 Korean MERS outbreak, we conducted a long-term follow-up study and found that although neutralizing antibodies and memory T cells against MERS-CoV declined over 5 years, some recovered patients exhibited increased antibody levels during the COVID-19 pandemic. This likely resulted from cross-reactive immunity induced by SARS-CoV-2 vaccines or infections. A significant correlation in antibody responses across various CoVs indicates shared immunogenic epitopes. Two epitopes-the spike protein's stem helix and intracellular domain-were highly immunogenic after MERS-CoV infection and after SARS-CoV-2 vaccination or infection. In addition, memory T cell responses, especially polyfunctional CD4+ T cells, were enhanced during the pandemic, correlating significantly with MERS-CoV spike-specific antibodies and neutralizing activity. Therefore, incorporating these cross-reactive and immunogenic epitopes into pan-CoV vaccine formulations may facilitate effective vaccine development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Science advances - 10(2024), 9 vom: 28. März, Seite eadk6425 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, So-Hee [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 01.03.2024 Date Revised 01.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1126/sciadv.adk6425 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36906755X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36906755X | ||
| 003 | DE-627 | ||
| 005 | 20240301232756.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1126/sciadv.adk6425 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1313.xml |
| 035 | |a (DE-627)NLM36906755X | ||
| 035 | |a (NLM)38416834 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, So-Hee |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rise in broadly cross-reactive adaptive immunity against human β-coronaviruses in MERS-recovered patients during the COVID-19 pandemic |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.03.2024 | ||
| 500 | |a Date Revised 01.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a To develop a universal coronavirus (CoV) vaccine, long-term immunity against multiple CoVs, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, Middle East respiratory syndrome (MERS)-CoV, and future CoV strains, is crucial. Following the 2015 Korean MERS outbreak, we conducted a long-term follow-up study and found that although neutralizing antibodies and memory T cells against MERS-CoV declined over 5 years, some recovered patients exhibited increased antibody levels during the COVID-19 pandemic. This likely resulted from cross-reactive immunity induced by SARS-CoV-2 vaccines or infections. A significant correlation in antibody responses across various CoVs indicates shared immunogenic epitopes. Two epitopes-the spike protein's stem helix and intracellular domain-were highly immunogenic after MERS-CoV infection and after SARS-CoV-2 vaccination or infection. In addition, memory T cell responses, especially polyfunctional CD4+ T cells, were enhanced during the pandemic, correlating significantly with MERS-CoV spike-specific antibodies and neutralizing activity. Therefore, incorporating these cross-reactive and immunogenic epitopes into pan-CoV vaccine formulations may facilitate effective vaccine development | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Epitopes |2 NLM | |
| 700 | 1 | |a Kim, Yuri |e verfasserin |4 aut | |
| 700 | 1 | |a Jeon, Sangeun |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Uni |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Ju-Il |e verfasserin |4 aut | |
| 700 | 1 | |a Jeon, Kyeongseok |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Hye-Ran |e verfasserin |4 aut | |
| 700 | 1 | |a Oh, Songhyeok |e verfasserin |4 aut | |
| 700 | 1 | |a Rhee, Ji-Young |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Jae-Phil |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Wan Beom |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Sang Won |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jeong-Sun |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Joo-Yeon |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Jihye |e verfasserin |4 aut | |
| 700 | 1 | |a Shin, Hyoung-Shik |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Yeonjae |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Seungtaek |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Yeon-Sook |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Dong-Gyun |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, Nam-Hyuk |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Science advances |d 2015 |g 10(2024), 9 vom: 28. März, Seite eadk6425 |w (DE-627)NLM247717614 |x 2375-2548 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2024 |g number:9 |g day:28 |g month:03 |g pages:eadk6425 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1126/sciadv.adk6425 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2024 |e 9 |b 28 |c 03 |h eadk6425 | ||